Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | POLE V411L |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
POLE V411L | endometrial cancer | predicted - sensitive | Nivolumab | Case Reports/Case Series | Actionable | In a Phase II trial, Opdivo (nivolumab) resulted in a partial response in two patients with endometrial cancer harboring POLE V411L, along with high tumor mutational burden (PMID: 35398880; NCT03012581). | 35398880 | |
POLE V411L | melanoma | sensitive | unspecified PD-1 antibody | Preclinical | Actionable | In a preclinical study, a murine anti-PD1 antibody inhibited tumor growth in a syngeneic mouse model of melanoma expressing POLE V411L (PMID: 35817971). | 35817971 | |
POLE V411L | colorectal cancer | predicted - sensitive | Ipilimumab + Nivolumab | Case Reports/Case Series | Actionable | In a retrospective study, treatment with immune checkpoint inhibitors resulted in an overall response rate of 89% (22/29) and a disease control rate of 92% in metastatic colorectal cancer patients harboring pathogenic POLE/POLD1 variants, including a partial response in two patients harboring POLE V411L treated with the combination of Yervoy (ipilimumab) and Opdivo (nivolumab) (PMID: 38777726). | 38777726 | |
POLE V411L | colorectal cancer | predicted - sensitive | Pembrolizumab | Case Reports/Case Series | Actionable | In a retrospective study, treatment with immune checkpoint inhibitors resulted in an overall response rate of 89% (22/29) and a disease control rate of 92% in metastatic colorectal cancer patients harboring pathogenic POLE/POLD1 variants, including a partial response in two patients harboring POLE V411L treated with Keytruda (pembrolizumab) (PMID: 38777726). | 38777726 |